PPARγ ligand rosiglitazone has been successfully used as insulin-sensitizing drugs in patients with type 2 diabetes mellitus and exerts beneficial effects on the kidney to ameliorate proteinuria and inflammation [23, 24]. The gene discussed is INS; the disease is type 2 diabetes mellitus.